SEELQ.US Seelos Therapeutics, Inc.

Healthcare Biotechnology USA Stocks
0.0000 USD
Close of Nov 18, 2026
Market cap
USD 5.00
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2024.

Is SEELQ.US undervalued?

Graham number

The Graham number of Seelos Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Seelos Therapeutics, Inc. fundamental analysis

No fundamental analysis for Seelos Therapeutics, Inc. yet.

Seelos Therapeutics, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Seelos Therapeutics, Inc.

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the trea…

Full company profile